Motavizumab

Motavizumab is a humanized monoclonal antibody. It is being investigated by MedImmune for the prevention of respiratory syncytial virus infection in high-risk infants., it was undergoing Phase II and III clinical trials.
In June 2010, the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune's request for licensure of motavizumab in a 14 to 3 decision. The members of that panel cited several reasons for the decision, and many were concerned that "we're not looking at a product that has evidence of superiority in terms of efficacy" when compared to the already available monoclonal antibody palivizumab.
In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m after discontinuing a key development program for motavizumab. The company stated that it would no longer develop motavizumab for the prevention of respiratory syncytial virus, and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop motavizumab for other treatments of RSV.